Market capitalization | $66.02m |
Enterprise Value | $132.91m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.11 |
P/S ratio (TTM) P/S ratio | 1.55 |
P/B ratio (TTM) P/B ratio | 2.37 |
Revenue growth (TTM) Revenue growth | 182.02% |
Revenue (TTM) Revenue | $42.69m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast Celularity Inc - Ordinary Shares - Class A:
1 Analyst has issued a forecast Celularity Inc - Ordinary Shares - Class A:
Jun '24 |
+/-
%
|
||
Revenue | 43 43 |
182%
182%
|
|
Gross Profit | 17 17 |
275%
275%
|
|
EBITDA | -36 -36 |
67%
67%
|
EBIT (Operating Income) EBIT | -45 -45 |
63%
63%
|
Net Profit | -113 -113 |
36%
36%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Celularity, Inc. a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The firms CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. It is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. The company is headquartered in Florham Park, NJ.
Head office | United States |
CEO | Robert Gordon |
Employees | 120 |
Founded | 2016 |
Website | www.celularity.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.